Serotonin News and Research

Latest Serotonin News and Research

Antidepressant treatment results in lower rate of MSIMI

Among patients with stable coronary heart disease and mental stress-induced myocardial ischemia (MSIMI), 6 weeks of treatment with the antidepressant escitalopram, compared with placebo, resulted in a lower rate of MSIMI, according to a study in the May 22/29 issue of JAMA.

22 May 2013

UTMB researchers awarded grant to study gene therapy techniques to eliminate neuropathic pain

University of Texas Medical Branch at Galveston researchers have been awarded a five-year, $1.8 million grant by the National Institute of Neurological Disorders and Stroke to apply the techniques of gene therapy to the problem of neuropathic pain - that is, pain that arises from a malfunction in the nervous system.

21 May 2013

Patients with treatment-resistant depression benefit from ketamine

Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the Icahn School of Medicine at Mount Sinai.

20 May 2013

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.

20 May 2013

Depression and time perception: an interview with Dr Rachel Msetfi, University of Limerick

In clinical terms, depression is defined by the presence of a cluster of symptoms. The Diagnostic Manual used by many psychologists and psychiatrists cites nine symptoms of depression, of which five must be present for a two-week period.

16 May 2013

Findings could help develop new approaches to treat depression and memory loss in the elderly

Scientists have known for some time that exercise induces neurogenesis in a specific brain region, the hippocampus. However, until this study, the underlying mechanism was not fully understood.

14 May 2013

New challenges to military medicine

Better body armor and rapid aeromedical evacuations enable American service members to survive blasts that would have proved fatal in Vietnam or even the first Gulf War, but they pose new challenges to military medicine - how to deal with the excruciating pain of injuries, especially severe burns from IED blasts that body armor can't protect.

13 May 2013

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries.

8 May 2013

SSRIs associated with increased risk of bleeding, transfusion, readmission and death

Selective serotonin reuptake inhibitors (SSRIs) - among the most widely prescribed antidepressant medications - are associated with increased risk of bleeding, transfusion, hospital readmission and death when taken around the time of surgery, according to an analysis led by researchers at UC San Francisco and Baystate Medical Center in Springfield, Mass.

30 Apr 2013

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

22 Apr 2013

FDA agrees to allow ADial to move forward with Phase III trial of AD04 for alcohol use disorder

ADial Pharmaceuticals, LLC, announced today that the U.S. Food and Drug Administration has agreed to allow ADial to move forward with its plan to initiate Phase III trials of AD04 as a treatment for alcohol use disorder in certain targeted genotypes population only.

19 Apr 2013

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

10 Apr 2013

Nine Nobel laureates to present their research at American Chemical Society meeting

At least nine Nobel laureates have research that will be presented here this week during the 245th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society.

8 Apr 2013

Duloxetine drug alleviates pain from chemotherapy

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA.

3 Apr 2013

Study shows why certain drugs that interact with serotonin receptors have harmful effects

A team including scientists from The Scripps Research Institute (TSRI), the University of North Carolina at Chapel Hill and the Chinese Academy of Sciences has determined and analyzed the high-resolution atomic structures of two kinds of human serotonin receptor.

25 Mar 2013

Serotonin News and Research

Latest Serotonin News and Research

Antidepressant treatment results in lower rate of MSIMI

UTMB researchers awarded grant to study gene therapy techniques to eliminate neuropathic pain

Patients with treatment-resistant depression benefit from ketamine

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Depression and time perception: an interview with Dr Rachel Msetfi, University of Limerick

Findings could help develop new approaches to treat depression and memory loss in the elderly

New challenges to military medicine

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

SSRIs associated with increased risk of bleeding, transfusion, readmission and death

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

FDA agrees to allow ADial to move forward with Phase III trial of AD04 for alcohol use disorder

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Nine Nobel laureates to present their research at American Chemical Society meeting

Duloxetine drug alleviates pain from chemotherapy

Study shows why certain drugs that interact with serotonin receptors have harmful effects

Study reveals treatments for pain at site of injury may not always be good enough

Alarming report on persistent side effects of antidepressant drugs published online

SSRI antidepressants taken during pregnancy do not impact infant's growth over the first year

Study challenges role of serotonin in depression, opens possibilities for new therapies

Study shows how oils and fats regulate feeling of satiety

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Serotonin News and Research

Latest Serotonin News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in